A new European clinical trial called PrevenTron is launching in Britain to test if the drug trontinemab can prevent dementia in healthy adults. The study focuses on middle-aged participants who show no memory loss but possess biological markers of the disease.
Trontinemab's faster plaque clearance compared to lecanemab
The PrevenTron trial centers on a drug called trontinemab, developed by the Swiss pharmaceutical company Roche. According to the report, trontinemab is designed to enter the brain more efficiently than previous treatments to attack amyloid, the sticky protein associated with Alzheimer's. While earlier drugs like lecanemab and donanemab typically required over a year to remove similar levels of amyloid, trontinemab appears to clear these toxic plaques substantially faster.
This shift in strategy is what experts are calling a "statins-for-the-brain" approach. Just as statins are prescribed to high-risk individuals to prevent heart disease before a cardiac event occurs, Roche is testing whether trontinemab can stop Alzheimer's from developing in the first place, rather than attempting to slow a decline that has already begun.
The 1,600-person PrevenTron study across 15 UK centers
The global PrevenTron study will recruit approximately 1,600 healthy adults between the ages of 55 and 80. In Britain, more than 15 hospitals and clinics are expected to participate, with the Surrey and Borders Partnership NHS Foundation Trust serving as the lead recruitment site in the UK. The trial is designed to last between four and six years, during which participants will be randomly assigned to receive either the active drug or a placebo.
Professor Ramin Nilforooshan, the chief investigator for the PrevenTron trial, noted that Alzheimer's pathology is believed to begin five to 10 years before a patient typically seeks help for memory loss. By intervening during this silent window, the study aims to determine if the drug can fundamentally delay or prevent the onset of cognitive impairment.
Using p-tau217 blood tests to find silent Alzheimer's
To identify the right candidates, the PrevenTron trial employs a rigorous screening process. Potential participants first undergo memory tests to ensure they have no significant cognitive issues.. They then receive a blood test to measure p-tau217, a specific protein that serves as a biological red flag for Alzheimer's even in the absence of symptoms.
As the report says, those with elevated p-tau217 levels will undergo further diagnostic investigations, including MRI and PET scans, before being enrolled. This precision screening ensures that the drug is targeted at individuals who are biologically predisposed to the disease, even if they currently feel healhy.
The NHS cost-effectiveness barrier for existing dementia drugs
The urgency of the PrevenTron trial is underscored by the devastating toll of dementia in Britain,which claims 76,000 lives annually. With nearly one million people currently living with the condition—a number forecast to hit 1.4 million by 2040—the need for a preventative solution is crtical. However, the path to widespread use is fraught with economic hurdles.
Previous drugs that slowed cognitive decline, specifically lecanemab (by 27%) and donanemab (by 35%), were licensed in Britain but ultimately rejected for routine NHS use.. The rejection came after officials determined these treatments were not cost-effective, highlighting a tension between clinical efficacy and the financial constraints of public healthcare.
Whether Roche's drug can avoid the NHS's previous rejections
Despite the optimism, significant questions remain regarding the ultimate viability of trontinemab. Professor Ramin Nilforooshan has cautioned that the drug is an investigational medicine and not "magic," leaving it unclear whether clearing amyloid plaques actually translates to a guaranteed prevention of memory loss.
Furthermore, the source does not detail the projected pricing for trontinemab. If the drug proves effective but carries a price tag similar to its predecessors, it remains an open question whether the NHS will find the preventative model cost-effective enough to implement on a national scale.
Comments 0